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1. Introduction
  Cervical cancer is a malignant tumor with the second 
highest incidence following breast cancer. The morbidity 
and mortality of cervical cancer in China account for 1/3 of 
the incidences in the world[1]. It is reported there is 459 000 
new cases every year, most of which occurs in China (13 1500 
cases, 28.7%)[2].  
  It takes 58 months for development of cervical 
intraepithelial neoplasia (CIN)Ⅰto cancer in situ, and 38 
months and 12 months for CIN 栻 and CIN 栿, respectively[3]. 
And it takes about 10 years for precancerous lesion to 
develop into infiltrating carcinoma[4]. It is also reported 
that the incidence is 0.69%-6.20% 4.3%-13.3%, and 
12.0%-65.0% for CIN 栺, CIN 栻 and CIN 栿to deterioate into 
cancer, respectively[5]. The five-year survival rate of cervial 
cancer patients with surgery at early stage is 80%-90%. So 
prompt and highly efficient screening is the key to decrease 
morbidity and to increase cure rate.
  The sensitivity and specificity of liquid-based cytological 
test (TCT) are 73%-94%, and 58%-76%, respectively. It 
is reported 92.9% cases with squamous intraepithelial 
lesion (HSIL) and 100.0% squamous cell cancer (SCC) were 
diagnosed by TCT, compared with 77.8% and 90.9% by 
traditional smear[6-8].  
  Cervical cancer is closely related to high risk human 
papilloma virus(HR-HPV). It is reported HPV DNA was 
detected in 95%-100% patients[9], and cervical cancer 
is hardly found in patients with negative HPV[10]. Now 
hybrid capture (HC) 栻 is regarded as a method with high 
sensitivity and specifity. It shows highest sensitivity and 
highest negative preditive value in some research, and has 
high consistency to the result of hispathological test[11-15].
  TruScreen is new real-time photoelectric screening 
method for cervical cancer. It has been approved in clinical 
application in Australia, and later gets the certification in 
Europe and Japan[16]. As cervical lesion occurs, epithelial 
cell nucleus enlarges, with increasing density and irregular 
shape, etc. These changes are collected by penetrating 
Objective: To explore the application of cervical cancer screening system, TruScreen in detecting 
atypical squamous cell of undetermined significance (ASCUS) patients. Methods: A total of 42 
cases were selected, who were diagnosed as ASCUS by thinprep cytologic test (TCT). Area from 
site 15 to 20, site 21 to 32 were detected by TruScreen. And the result was compared with those 
of cases which had positive pathological result of cervical biopsy. Results: There were 16 cases 
with abnormal pathological result in ASCUS cases, including 6 cases with cervical intraepithelial 
neoplasia (CIN) 栺, 6 cases with CIN栻, 3 cases with CIN栿 and 1 case with infiltrating carcinoma. 
The consistency between TCT and pathological test was 38.10% (16/42). The positive rate of 
TruScreen at site 15-20 was 61.91% (26/42). There was significant difference in consistency with 
pathological test between TCT and TruScreen (x2=4.762, P=0.029). The positive rate of TruScreen 
at site 21-32 was 66.67% (28/42)(Kappa=0.181, P=0.016). There was significant difference in 
consistency with pathological test between TCT and TruScreen (x2=9.4919, P=0.002).And no 
case was missed when site 21-32 of patients with CIN栻 and above were detected by TruScreen. 
Conclusions: TruScreen is effective in detecting ASCUS patients.
Weihong Li et al./Asian Pacific Journal of Tropical Medicine (2011)669-671670
photoelectric wave, then analyzed by database. It is in time, 
convenient, rapid, and free of wound and pain.  
  TruSreen has been applied since 2007. It is reported by 
Singer, Zanardi, Itzkowic, Abdul et al[16-19]l and researchers 
in China[20-23] that combination screening of TruScreen 
and cervical smear is of high sensitivity, specificity and 
consistency with pathological result.
2.Materials and methods
2.1. Subjects
  A total of 42 cases, who were admitted from December 2010 
to May 2011 and were diagnosed as atypical squamous cell 
of undetermined significance (ASCUS) by TCT, were selected. 
The age was 22-53 years old. 
2.2. Cervical cancer screening syetem detection
  Cervical cancer screening syetem (Polartechnics Lt.Co., 
Australian) was used according to manual. Handle controler 
with disposable inducer was placed into vaginal to probe at 
site 15-20 and site 21-32.  
2.3. Pathological test
  The tissues with abnormal result of cervical cancer 
screening system, TruScreen were selected for biopsy and 
normal tissues from sites 3, 6, 9 and 12 were also selected for 
pathological examination.
2.4. Statistic analysis
  Kappa consistency test and x2 test were carried out for 
statistic analysis.
3. Results
  Pathological results showed 16 cases with positive result, 
including 6 cases with CIN 栺, 6 cases with CIN栻, 3 cases 
with CIN栿 and 1 case with infiltrating carcinoma. The 
consistency between TCT and pathological test was 38.10% 
(16/42). The positive rate of TruScreen at site 15-20 was 
61.91% (26/42). There were 13 cases with positive result 
both of pathological test and TruScreen, including 4 cases 
with CIN 栺, 5 cases with CIN栻, 3 cases with CIN栿 and 1 
case with infiltrating carcinoma. And there were 13 cases 
with negative result in two tests. Consistency test showed 
significant consistency between two tests (Kappa＝0.279，
P＝0.043). There was significant difference in consistency 
with pathological test between TCT and TruScreen (x2=4.762, 
P=0.029). 
  The consistency rate between TCT and pathological test 
was 38.10% (16/42). The positive rate of TruScreen at site 
21-32 was 71.43% (30/42), and the consistency rate between 
TruScreen and pathological test was 66.67% (28/42). There 
were 16 cases with positive result both of pathological 
test and TruScreen, including 6 cases with CIN 栺, 6 cases 
with CIN栻, 3 cases with CIN栿 and 1 case with infiltrating 
carcinoma. And there were 12 cases with negative result in 
two tests. Consistency test showed significant consistency 
between two tests (Kappa＝0.181, P＝0.016) . There was 
significant difference in consistency with pathological test 
between TCT and TruScreen (x2=9.419, P=0.002).
4. Discussion
  ASCUS is a cell between normal squamous cell and 
abnormal cell, with higher cellular reactivity but not as high 
as cervical squamous intraepithelial neoplasia in quality 
and quantity[1]. Due to incomplete tissue morphology of 
smear, it is difficult to determine the existence of squamous 
intraepithelial neoplasia. ASCUS is a common type with low 
repetitiveness of test. Detection rate of invasive carcinoma of 
cervix and precancerous lesion are low in ASCUS patients[25].
  Pathological positivity of ASCUS patients is 38.1% in 
this study, and incidence of patients with CIN栻and above 
is 62.5% (10/16). It indicates ASCUS need be paid more 
attention to. It is proposed that vaginoscopy is necessary for 
ASCUS patients[26]. Some proposed that repetitive cytological 
test should be performed[27], and some held the point that 
HPV should be tested firstly, and then vaginoscopy is used if 
the result is positive[28]. It is reported by Song et al positive 
rate of HR HPV DNA is 40%-51%, HR HPV DNA test can be 
performed by HC-2 method separate ill-free people and sick 
patients[25].
  Zanardi et al conducted a study on 37 cases diagnosed 
as ASCUS by cytological test. The consistency between 
TruScreen and pathological test was 81%. They thought 
TruScreen can make effective screening on ASCUS patients 
or patients with unclear cyological result. We use Kappa 
consistency test to determine the consistency between 
TruScreen and pathological result, and it showed significant 
consistency (Kappa＝0.279, P＝0.043 for site 15-20, and 
Kappa＝0.181, P＝0.016 for site 21-32). It indicates that 
result of TruScreen is consisitent to pathological result, and 
TruScreen is helpful in screening ASCUS patients. Besides, 
no case with high CIN level was missed. It indicates that in 
contrast to HR HPV DNA test, TruScreen is more helpful in 
separation of ASCUS patients. Due to limited cases, the value 
of TruScreen need further investigation with larger cases. 
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